mRNA Vaccines/Drugs and mRNA Technology
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Vaccines and Therapeutic Developments".
Deadline for manuscript submissions: 10 July 2026 | Viewed by 16
Special Issue Editor
Interests: mRNA vaccines and drugs; extrahepatic targeted delivery of nucleic acid drugs; anti-bacteria therapeutics; antibody–drug conjugates (ADCs); endolysin engineering
Special Issue Information
Dear Colleagues,
mRNA technology has emerged as a transformative tool in combating infectious diseases, offering flexible antigen design, rapid development cycles, and potent immunogenicity. Innovations such as self-amplifying mRNA, circular mRNA, and advanced delivery systems (e.g., LNP) further amplify its potential for pathogen-targeted interventions, paving the way for novel anti-infective strategies.
This Special Issue of Pathogens focuses exclusively on mRNA technology’s applications in preventing and treating pathogenic infections. We welcome submissions covering antigen optimization for viruses, bacteria, and parasites; the development of self-amplifying/circular mRNA platforms; novel mRNA delivery systems (e.g., LNP, polymer-based carriers) and delivery efficiency optimization; mRNA-based anti-infective therapies; immune activation mechanisms; and preclinical/clinical efficacy and safety evaluations. Manuscript types include original research, reviews, mini-reviews, and perspectives.
Join us to advance mRNA innovations in pathogen control and prevention, and accelerate their translation into clinical practice. We look forward to receiving your valuable contributions.
Dr. Yunjiao He
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mRNA vaccines
- mRNA technology
- pathogen control
- self-amplifying mRNA
- circular mRNA
- mRNA delivery systems
- anti-infective therapies
- antigen optimization
- immune activation and mechanism
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
